Q32 Bio (QTTB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnin ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 19:FIGS, Inc. (FIGS) : This healthcare apparel company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 90% over the last 60 days.FIGS's shares gained 18.6% over the last three months compared with the S&P 500’s decline of 1.5%. The company possesses a Momentum Score of A.Q32 Bio Inc. (QTTB) : This biotechnology company has a Zacks Rank #1 and ...

Shares of Q32 Bio (QTTB) have gained 83.8% over the past four weeks to close the last trading session at $7.04, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.33 indicates a potential upside of 103.6%.The average comprises three short-term price targets ranging from a low of $10.00 to a high of $20.00, with a standard deviation of $5.13. While the lowest estimate indicates ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-38433 Q32 Bio Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 47-346815 ...

Exhibit 99.1 Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics to further enable Company's strategic focus on advancing bempikibart for a ...

1 Building The Future of Immune Therapeutics Company Overview March 2026 Forward Looking Statements This presentation has been prepared byQ32 Bio Inc. ("we", "us," "our," "Q32" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances cre ...

Core Viewpoint - Q32 Bio reported a significant turnaround in financial performance for Q4 2025, achieving a net income of $57.7 million, driven by collaboration revenue and the sale of ADX-097, while focusing on advancing bempikibart for alopecia areata [1][2]. Financial Results - Net income for Q4 2025 was $57.7 million, translating to $4.60 per basic share and $4.58 per diluted share, compared to a net loss of $14.2 million in Q4 2024 [2][3]. - For the full year 2025, net income was $29.8 million, or $2.42 per share, compared to a net loss of $47.7 million in 2024 [2][3]. - General and administrative expenses were $4.5 million for Q4 2025, up from $4.0 million in Q4 2024, while full-year expenses decreased to $17.7 million from $18.0 million [2]. - Research and development expenses significantly decreased to $3.3 million for Q4 2025 from $10.5 million in Q4 2024, and for the full year, they dropped to $19.2 million from $48.1 million [2]. Corporate Updates - Q32 Bio completed a $10.5 million registered direct offering in February 2026, issuing 1,666,679 shares at $3.90 each [1][2]. - The company sold the Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront, with potential total payments of up to $592 million based on future milestones [1][2]. - Enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial was completed, increasing the trial size to 33 patients, with topline data expected in mid-2026 [1][2]. Clinical Development - Bempikibart, a fully human anti-IL-7R antibody, is being evaluated in the SIGNAL-AA Phase 2a clinical trial for alopecia areata, with promising pharmacokinetic data suggesting earlier responsiveness [1][2]. - The trial aims to assess efficacy based on changes in Severity of Alopecia Tool (SALT) scores, with follow-up extending to 52 weeks [1][2].

Summary of Q32 Bio FY Conference Call Company Overview - **Company**: Q32 Bio (NasdaqGM:QTTB) - **Focus**: Development of bempikibart, a fully human antibody targeting alopecia areata and other diseases Key Points and Arguments Product Development - **Lead Asset**: Bempikibart is the primary focus, currently in development for alopecia areata, with proof of concept already established [2][3] - **Mechanism of Action**: Bempikibart binds to the IL-7 alpha receptor, blocking Th2 and Th1 cytokine signaling, which may provide broad therapeutic benefits across various diseases [2] - **Market Potential**: The alopecia areata market is expected to reach $2.6 billion by 2030, with a significant unmet need for biologics in this space [3] Clinical Trials - **SIGNAL-AA Study**: - Part A completed with positive results, leading to an open-label extension due to high patient demand [4] - Part B has enrolled 33 patients, with top-line data expected by mid-year 2026 [4][17] - The study design includes a 36-week dosing period and a focus on patient safety and response durability [9][10] Efficacy and Safety - **Part A Results**: Showed a statistically significant drop in SALT percentage, indicating meaningful hair growth responses [5][6] - **Durability of Response**: Continued hair growth observed even after treatment cessation, suggesting potential advantages over JAK inhibitors [6][7] - **Safety Profile**: Bempikibart's safety profile is favorable compared to JAKs, positioning it as a safer alternative for chronic use [8][12] Market Dynamics - **Current Treatment Landscape**: JAK inhibitors are the only approved treatments for alopecia areata, but their market penetration remains limited [25][26] - **Commercial Opportunity**: Bempikibart is expected to penetrate the market significantly and expand it, similar to trends seen with biologics in other conditions [25][26] Future Directions - **Phase III Plans**: Efficacy signals from Part B will inform the design of Phase III studies, with a target for SALT 20 responses in the mid-20s percentage range [61][62] - **Potential Indications**: While alopecia areata remains the primary focus, there are opportunities for bempikibart in other inflammatory diseases such as ulcerative colitis and celiac disease [61][62] Financials and Strategic Moves - **Partnership with Akebia**: Q32 Bio sold ADX-097 to Akebia for $12 million upfront, with potential total milestones of up to $592 million, allowing the company to focus on bempikibart [65][66] Conclusion - **Upcoming Milestones**: Anticipation for mid-year 2026 top-line results from the SIGNAL-AA study, which are expected to be significant for the company's future [68] This summary encapsulates the key points discussed during the conference call, highlighting Q32 Bio's strategic focus on bempikibart, its clinical development progress, market potential, and future directions.

Core Insights - Q32 Bio Inc. is a clinical stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune diseases [1] - The company will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, with a webcast available for 90 days post-event [1] Company Overview - Q32 Bio targets potent regulators of the adaptive immune system to develop innovative therapies for alopecia areata and other autoimmune and inflammatory diseases [1] - Approximately 700,000 individuals in the U.S. are affected by alopecia areata, which significantly impacts their lives and has limited treatment options [1] Product Development - Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R antibody, currently in a Phase 2 program for treating alopecia areata [1] - The IL-7 and TSLP pathways are implicated in various T cell-mediated autoimmune diseases, highlighting the potential of Q32 Bio's therapeutic approach [1]

Core Insights - Q32 Bio's shares more than doubled following a strategic deal with Akebia Therapeutics, indicating strong market interest and validation of its complement inhibitor platform [1][3] - The deal involves an upfront payment of $12 million for the Phase complement inhibitor ADX-097, with potential total transaction value reaching $592 million through various milestones [1][3] - The transaction allows Q32 Bio to monetize a key asset while retaining rights to its broader tissue-targeted complement inhibitor platform, which includes ADX-096 for ophthalmologic indications [3] Financial Implications - The divestment of ADX-097 provides immediate cash flow and long-term revenue potential through tiered royalties ranging from low single-digit to mid-teen percentages on future sales [4] - The company plans to refocus on advancing Bempikibart, a treatment for alopecia areata, which represents a strategic pivot that may enhance stock value in 2026 [4] Market Reaction - At its peak, Q32 Bio stock traded nearly 350% above its year-to-date low, but closed the session at $3.82, reflecting a 75% increase on the day [2] - Despite the positive outlook from the Akebia deal, there are concerns regarding the sustainability of the stock's rapid price increase and inherent execution risks associated with biotech investments [5][6]